This medication is associated with multiple symptomatic and therapeutic applications.

---

Therapeutic Scope and Patient Benefits

The primary therapeutic use of Stella is to provide support for reversible, systemic contraception for women of reproductive age. This medication plays a role in managing continuous pregnancy prevention and contributes to maintaining predictable control over their reproductive health decisions.

Stella is commonly used to address distressing symptoms related to the menstrual cycle. It provides support by contributing to cycle regularity and may assist with easing the symptomatic discomfort related to dysmenorrhea (severe menstrual pain) and heavy menstrual bleeding (menorrhagia). This application helps to ease the overall symptom load and supports improved day-to-day comfort during symptomatic periods.

For patients seeking treatment for moderate acne vulgaris, particularly when symptoms are linked to hormonal influences, the medication is considered relevant. It is applied when patients elect to use oral contraception, and may assist with addressing acne lesions and symptoms related to skin greasiness. This supports general well-being and may contribute to improved skin clarity.

---

Quick Facts

Quick Fact:	Symptom Support Area
Primary Use	Support for Reversible Contraception
Menstrual Support	Symptoms of Dysmenorrhea and Heavy Bleeding
Dermatological Support	Symptoms of Moderate Acne and Skin Greasiness

Regulatory References

1. European Medicines Agency

Who can and cannot use Stella?

The eligibility for Stella (Dienogest / Ethinyl Estradiol) is strictly defined by regulatory bodies and centers on pre-existing health risks, particularly those related to blood clot formation and hormone sensitivity.

Contraindicated Populations

Use is absolutely contraindicated in women who smoke and are over age 35. It is also prohibited for women with a high risk of arterial or venous thrombotic diseases, including a history of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, or known hypercoagulopathies. Additional contraindications include current or history of breast cancer or other hormone-sensitive cancers, liver tumors, or acute liver disease. Stella is contraindicated during pregnancy and in cases of migraine headaches with aura.

Age and Condition Restrictions

The medicine is indicated for postpubertal women of reproductive age and is not indicated for use before menarche or in postmenopausal women. Use is also prohibited in cases of uncontrolled hypertension or diabetes mellitus with vascular disease. Women must stop taking the medicine at least 4 weeks before and through 2 weeks after major surgery due to the increased risk of blood clots. Stella is not recommended for women who are breastfeeding.

Interactions with other medicines and products

This medication's official interaction profile is defined by pharmacokinetic changes that alter the plasma concentrations of its hormonal components, which may affect its efficacy or safety.

Property	Description
Medicinal product categories with documented interactions:	Enzyme Inducers (e.g., antiepileptics), HCV Combinations, Enzyme Inhibitors (e.g., antifungals, statins), Bile Acid Sequestrants, and certain Dietary Supplements/Herbal Products.
Mechanistic basis of interactions (only if stated in label):	Enzyme induction (leading to reduced hormone concentration), Enzyme inhibition (leading to increased hormone concentration), and binding/sequestration.
Timing-based interaction rules (if applicable):	The Bile Acid Sequestrant Colesevelam must be administered at least 4 hours apart from this medication to mitigate the documented reduction in ethinyl estradiol exposure.
Population-specific interaction notes (if applicable):	Co-use with tobacco (cigarette smoking) is contraindicated for women over 35 years old due to a significantly increased risk of serious cardiovascular events.
Interaction-related restrictions:	Combinations with strong enzyme inducers and specific HCV combination therapies are contraindicated.

Official Interaction Statements

• Co-administration with HCV combination therapies containing Ombitasvir/Paritaprevir/Ritonavir is contraindicated.
• The use of strong CYP enzyme-inducing medicines (e.g., Rifampicin, St. John's Wort) may reduce the plasma concentrations of the active ingredients, which can lead to a loss of contraceptive protection.
• Substances that inhibit CYP enzymes (e.g., Ketoconazole, Grapefruit Juice) may increase the plasma concentrations of the hormonal components.
• Substances like Atorvastatin and Ascorbic acid are documented to increase the plasma concentration of Ethinyl Estradiol.

Connection to the Overall Interaction Profile

Regulatory documents define this product's interaction structure primarily through its hormonal components' metabolism, identifying numerous pharmacokinetic interactions that significantly reduce or increase hormone exposure. The profile includes strictly prohibited combinations with certain HCV therapies and a definitive population-specific restriction where the combination of the drug’s components with tobacco use in older women is strictly contraindicated.

How Stella Works: Mechanism of Action

---

Stella is an IgG1κ monoclonal antibody that functions as an antagonist by binding with high affinity to the shared p40 protein subunit of the Interleukin-12 (ⅬⅬ-12) and Interleukin-23 (ⅬⅬ-23) cytokines. This molecular action physically blocks both cytokines from engaging with their corresponding ⅬⅬ-12Rβ1 receptors on immune cells, thereby preventing the initiation of ⅬⅬ-12 and ⅬⅬ-23 signaling within the body.

This blockade effectively interrupts the specific intracellular STAT4 and STAT3 signaling pathways that drive the activation and differentiation of T cells into Th1 and Th17 subsets. Modifying these early molecular steps within the immune system results in a decreased production of numerous downstream pro-inflammatory molecules, such as ⅬⅬ-17 and IFNγ. The suppression of these central signaling pathways produces a systemic modulation of inflammatory processes by altering Ⅼ cell differentiation and ⅬⅬ-12/ⅬⅬ-23-driven inflammatory activity.

Stella is administered through the oral route as a film-coated tablet, following a precisely defined, continuous administration schedule. The regimen is based on taking one active tablet daily.

Usage Principle	Administration Detail
Dosing Schedule	One tablet is taken every day without interruption, typically containing 0.03 mg Ethinyl Estradiol and 2 mg Dienogest.
Treatment Cycle	Administration follows a 28-day cycle, which commonly consists of 21 active tablets followed by a 7-day period of hormone-free or placebo tablets.
Intake Timing	The tablet must be taken at approximately the same time each day, and the order of tablets indicated on the blister packaging must be followed strictly.

The duration of use for pregnancy prevention is continuous for as long as control is desired, while the clinical use in addressing moderate acne is typically assessed after three to six months of continuous therapy. Adherence to the scheduled daily intake time is a required component of its use. If the time of intake is delayed by more than 12 hours, the administration protocol indicates that its use may be compromised, requiring the follow-up instructions for a missed dose. Furthermore, if a gastrointestinal disturbance, such as vomiting or severe diarrhea, occurs within three to four hours of administration, the protocol for a missed dose must be followed, as this may hinder the complete absorption of the dose. It is specified that use is not indicated for postmenopausal women and that efficacy data has not been fully evaluated for women with a Body Mass Index (BMI) exceeding 30 kg/m^2.

Stella: Recent Clinical Evidence

Clinical evidence for Stella (ustekinumab) centers on its use for conditions driven by chronic inflammation, such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Primary Efficacy Findings

Studies investigated the proportion of adult participants who achieved key endpoints, such as clinical response or remission, typically measured at 8 to 12 weeks following initial treatment (induction) and then throughout maintenance phases (up to one year or more). Data from randomized trials reported that a measurable response occurred in a higher percentage of participants receiving Stella compared to those receiving a placebo.

Condition Studied	Primary Endpoint Measured
Plaque Psoriasis	Achievement of Psoriasis Area and Severity Index (PASI 75/90)
Psoriatic Arthritis	Achievement of American College of Rheumatology 20 (ACR20) response
Crohn's Disease	Clinical response and endoscopic remission
Ulcerative Colitis	Clinical response and mucosal healing

Long-Term Research and Safety

Long-term follow-up research has tracked the maintenance of response in participants over several years. These studies generally found that a continuous regimen was associated with sustained clinical benefit over time in a subset of patients who initially responded to treatment.

Safety monitoring across clinical trials indicated that the incidence of serious infections and the potential for malignancy are important considerations. Common adverse events reported across the studies included upper respiratory tract infections (such as nasopharyngitis), headache, and fatigue. Research also examined a rare but serious condition affecting the brain, Posterior Reversible Encephalopathy Syndrome (PRES), which was reported in some participants.

Key Studies & References

1. NICE Guideline: Ustekinumab for treating moderate to severe plaque psoriasis

Common questions about Stella (FAQ)

Q: How does Stella differ from other medicines that treat the same problem?

A: Official documents describe Stella as a combined hormonal contraceptive that contains the synthetic estrogen Ethinyl Estradiol and the progestogen Dienogest. Dienogest is specifically recognized for its antiandrogenic activity. This unique component helps differentiate its pharmacological profile from some other combined hormonal contraceptives.

Q: Is it common to feel tired after starting Stella?

A: According to official regulatory data, fatigue is listed as a common adverse reaction. This means it was reported in a frequency of 1/100 to <1/10 of participants in clinical studies.

Q: How does Stella specifically target the underlying condition?

A: The medication is classified as a combined hormonal contraceptive that functions primarily as a reliable ovulation inhibitor. The general purpose of the medication is pregnancy prevention through the coordinated hormonal action of its components on the body's endocrine system.

Q: Is it true that Stella is only for short-term use?

A: Official instructions indicate that the medicine is for continuous use for pregnancy prevention for as long as control is desired. Its use in addressing moderate acne is typically assessed after three to six months of continuous therapy, but the duration of use should be discussed with a healthcare provider.

Q: How important is the timing of taking Stella relative to meals?

A: Regulatory information indicates that the tablet can be taken without regard to meals. Regulatory documents emphasize the importance of taking the tablet at approximately the same time each day for use consistency.

Q: Is it safe to drive or operate machinery while taking Stella?

A: Official regulatory documents list dizziness and migraine as uncommon adverse reactions. If individuals experience these or other side effects that affect coordination, this information should be considered when operating vehicles or machinery.

Q: Is Stella used to treat chronic or acute conditions?

A: The medication is indicated for conditions that require ongoing management. This includes pregnancy prevention (which involves continuous use) and the treatment of moderate acne, which is also managed through a continuous therapy assessed over several months.

Q: What types of patients were included in the main clinical trials for Stella?

A: The medicine is indicated for postpubertal women of reproductive age. Official efficacy data has not been fully evaluated for all patient populations, including for women with a Body Mass Index (BMI) exceeding 30 kg/m^2.

Q: Does Stella start working immediately or does it take time?

A: Official instructions state that if the medication is started later than the first day of a menstrual cycle, it is not considered effective as a contraceptive until after the first 7 consecutive days of administration. The official protocol suggests that a non-hormonal method of contraception be considered during this initial period.

Q: What is the typical timeframe before noticing an effect from Stella?

A: The effect observed can depend on the indication. For the treatment of acne, continuous therapy is typically assessed after three to six months. Irregular uterine bleeding is often expected during the first few months of use as the body adjusts to the medication.

Q: How long does Stella usually stay in your system after taking it?

A: Pharmacokinetic studies indicate that the elimination half-life of the hormonal components is reported to be in the range of 15 to 28 hours.

Q: Are there common feelings or sensations people report when first taking Stella?

A: Common adverse reactions, which may be felt upon starting the medication, include headache, nausea, breast discomfort or tenderness, and irregular uterine bleeding. These are effects commonly reported in clinical trials.

Q: Can Stella affect your mood or mental focus?

A: Regulatory documents list depression or mood change as an uncommon side effect of the medication. A disturbance in attention has also been reported in rare cases.

Q: Can over-the-counter pain relievers interact with Stella?

A: Some common over-the-counter pain relievers, such as acetaminophen, are reported to have no known interaction with this medication. Regulatory information indicates that the official labeling for all concurrent medications and supplements may need to be reviewed, as other interactions are documented.

Q: Does alcohol consumption need to be avoided completely while taking Stella?

A: Regulatory interaction information suggests that the effects and blood levels of alcohol (ethanol) may be increased when combined with oral contraceptives. Official guidelines do not explicitly prohibit alcohol use, but indicate that its effects may be increased.

Q: What happens if a dose of Stella is missed?

A: If an active tablet is missed, the risk of pregnancy increases. The official protocol involves the use of a non-hormonal contraceptive as a back-up method until the pill is taken daily for seven consecutive days. Official instructions indicate that a patient must follow the protocol detailed in the product information.

Q: Are there any long-term studies available about the effects of Stella?

A: Research has examined the effects of continuous use and generally found that a continuous regimen was associated with sustained clinical benefit over time for certain indications. Long-term studies also track safety considerations such as the risk of serious vascular events.

Q: Is it normal to have mild headaches after starting Stella?

A: According to official documentation, headache is listed as a common adverse reaction, meaning it is one of the more frequently reported effects in clinical studies.

Q: What should be done if an unexpected symptom occurs while on Stella?

A: Official product information advises that a healthcare professional be contacted immediately if serious unexpected symptoms occur. This includes signs associated with a blood clot, a stroke, or liver problems.

Q: Can Stella be crushed or split?

A: The medication is administered as a film-coated tablet designed for the oral route. Official regulatory information does not typically specify whether the tablet can be altered unless it is scored or has specific instructions for doing so.

Q: Does taking Stella require regular blood tests?

A: Official prescribing information indicates that the medication may interfere with the results of certain laboratory tests. Regulatory guidance calls for monitoring of cardiovascular status, which may include laboratory evaluations.

Q: What is the risk of a severe allergic reaction to Stella?

A: Official patient warnings describe conditions for which emergency help may be required, such as the occurrence of signs of a severe allergic reaction. These signs may include hives, difficult breathing, or swelling of the face, lips, tongue, or throat.

Q: Are there known factors that make Stella less effective for some people?

A: Regulatory information specifies that if a gastrointestinal disturbance (vomiting or severe diarrhea) occurs within three to four hours of administration, the dose absorption may be hindered. Efficacy data is also not fully evaluated for women with a Body Mass Index (BMI) exceeding 30 kg/m^2.

Q: How soon after stopping Stella can I start taking other medications?

A: Official regulatory information specifies that the medicine must be stopped at least 4 weeks before and through 2 weeks after major surgery due to the increased risk of blood clots. This is a key safety interval defined in official documents.

Q: Does Stella affect fertility?

A: Studies have examined fertility after discontinuation and found that while there may be a slight delay in the return of fertility during the first few cycles, there is no evidence of a negative effect on long-term fertility.

Q: What if Stella doesn't seem to be working for me after the recommended time?

A: Official prescribing information indicates that a healthcare professional may need to evaluate unscheduled or breakthrough bleeding that persists more than a few cycles. Additionally, if two consecutive periods are missed, the possibility of pregnancy should be considered.

Q: What is the role of Stella in the overall management of the condition it treats?

A: The primary role of the medication is to serve as a highly effective and reversible form of birth control (pregnancy prevention). It is also recognized for use in the overall management of moderate acne.

The storage and disposal of Stella (Dienogest/Ethinyl Estradiol) must align with regulatory requirements to preserve the tablets' stability.

Requirement
Storage Temperature	Store at room temperature, ideally between 20 C to 25 C (68 F to 77 F). Avoid temperatures above 30 C (86 F) and keep from freezing
Protection Mandate	Keep the medication in the original container to protect it from moisture and direct light
Child Safety	Store this medication out of the reach of children and pets
Disposal Protocol	Do not dispose of unused or expired tablets in household waste or wastewater. Consult a pharmacist or healthcare professional for guidance on proper disposal